CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer.

ABSTRACT: Pancreatic cancer lacks effective therapy. Here, we reported two metastatic pancreatic cancer patients administrated with Claudin 18.2 (CLDN 18.2) CART therapy after the failure of standard therapy (NCT04581473 and NCT03874897). In case 1, with CLDN 18.2 expression of 2+, 70%, 250 × 10⁶ cells were infused after lymphodepletion. Grade 1 cytokine release syndrome (CRS) occurred on d1 which was later controlled by tocilizumab. Partial response (PR) was achieved according to RECIST v1.1, with great shrinkage of lung metastasis. An increasing CD8+ T cell and Treg cells and declining CD4+ T cell and B cell were observed. In case 2, IHC result of ClDN18.2 showed 3+, 60%. 250 × 10⁶ CLDN18.2 CART cells were subsequently administered. Patient experienced grade 2 CRS, which was

SUBMITTER: Qi C 

PROVIDER: S-EPMC10492318 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature